Esperion Therapeutics, Inc. announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at $2.50 per share, with an option to purchase an additional 4,500,000 shares, totaling approximately $75.0 million in gross proceeds. The offering is expected to close around October 9, 2025. The shares are being offered via an effective shelf registration statement, and Piper Sandler & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers.

Esperion is a biopharmaceutical company focused on developing accessible, oral, non-statin medicines for patients with elevated LDL-C. They are known for their FDA-approved oral medications and are working on next-generation ATP citrate lyase inhibitors. The company continues to grow through commercial execution and international partnerships. Forward-looking statements in the press release highlight the company’s beliefs and expectations regarding the public offering timing and closing.

Read more at GlobeNewswire: Esperion Announces Pricing of Public Offering of Common